These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 11439339)
1. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Munshi A; Pappas G; Honda T; McDonnell TJ; Younes A; Li Y; Meyn RE Oncogene; 2001 Jun; 20(29):3757-65. PubMed ID: 11439339 [TBL] [Abstract][Full Text] [Related]
2. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Ravi R; Bedi A Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014 [TBL] [Abstract][Full Text] [Related]
3. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Mitsiades N; Poulaki V; Mitsiades C; Tsokos M Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151 [TBL] [Abstract][Full Text] [Related]
4. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Ozören N; El-Deiry WS Neoplasia; 2002; 4(6):551-7. PubMed ID: 12407450 [TBL] [Abstract][Full Text] [Related]
5. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Voelkel-Johnson C; King DL; Norris JS Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034 [TBL] [Abstract][Full Text] [Related]
6. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279 [TBL] [Abstract][Full Text] [Related]
7. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Munshi A; McDonnell TJ; Meyn RE Cancer Chemother Pharmacol; 2002 Jul; 50(1):46-52. PubMed ID: 12111111 [TBL] [Abstract][Full Text] [Related]
8. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Kang J; Bu J; Hao Y; Chen F Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917 [TBL] [Abstract][Full Text] [Related]
9. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Zhang X; Jin TG; Yang H; DeWolf WC; Khosravi-Far R; Olumi AF Cancer Res; 2004 Oct; 64(19):7086-91. PubMed ID: 15466204 [TBL] [Abstract][Full Text] [Related]
10. Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis. Rokhlin OW; Guseva N; Tagiyev A; Knudson CM; Cohen MB Oncogene; 2001 May; 20(22):2836-43. PubMed ID: 11420695 [TBL] [Abstract][Full Text] [Related]
11. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850 [TBL] [Abstract][Full Text] [Related]
12. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Ng CP; Zisman A; Bonavida B Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140 [TBL] [Abstract][Full Text] [Related]